The treatment effect, reductions in urine protein levels, was on par with that observed in IgA nephropathy patients on steroid therapy.
Additional data will be submitted for presentation at a future medical conference.
A Phase 3 study, ARTEMIS-IGAN, is ongoing with an estimated primary completion date of May 2020.
Shares will resume trading at 2:45 pm ET.
Subscribe for full text news in your inbox